Harp MBA - Vaxcyte VP Chain
| PCVX Stock | USD 88.39 2.43 2.83% |
Insider
Harp MBA is VP Chain of Vaxcyte
| Age | 51 |
| Address | 825 Industrial Road, San Carlos, CA, United States, 94070 |
| Phone | 650 837 0111 |
| Web | https://vaxcyte.com |
Vaxcyte Management Efficiency
The company has return on total asset (ROA) of (0.1494) % which means that it has lost $0.1494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2106) %, meaning that it created substantial loss on money invested by shareholders. Vaxcyte's management efficiency ratios could be used to measure how well Vaxcyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.3 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, Vaxcyte's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 1.2 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| McDavid Stilwell | Coherus BioSciences | 52 | |
| Jason Cavalier | Lyra Therapeutics | 51 | |
| James Brady | Spero Therapeutics | N/A | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| Susannah Walpole | Spero Therapeutics | N/A | |
| Rebecca Sunshine | Coherus BioSciences | 61 | |
| Edward DVM | SAB Biotherapeutics | N/A | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| Karen Bergman | Bolt Biotherapeutics | N/A | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Satyavrat CFA | Spero Therapeutics | 51 | |
| Donald MBA | Lyra Therapeutics | 70 | |
| Randall Schatzman | Bolt Biotherapeutics | 69 | |
| Jeffrey Ecsedy | Ikena Oncology | 54 | |
| Evan Hecker | Ikena Oncology | N/A | |
| MBA MD | Spero Therapeutics | 43 | |
| Eddie Sullivan | SAB Biotherapeutics | 58 | |
| MBA CFA | Bolt Biotherapeutics | 60 | |
| Andrew MBA | Monopar Therapeutics | 52 | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
Management Performance
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.15 |
Vaxcyte Leadership Team
Elected by the shareholders, the Vaxcyte's board of directors comprises two types of representatives: Vaxcyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaxcyte. The board's role is to monitor Vaxcyte's management team and ensure that shareholders' interests are well served. Vaxcyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaxcyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mikhail JD, General VP | ||
| Karen Alderete, Ex HR | ||
| Whitney Jones, Chief Officer | ||
| Andrew MBA, President CFO | ||
| Ashish MBA, CoFounder Officer | ||
| Jeff Fairman, CoFounder Research | ||
| Grant MBA, CEO CoFounder | ||
| Harp MBA, VP Chain | ||
| MS MBA, Executive COO | ||
| Paul MBA, Senior Manufacturing | ||
| MBA MBA, Sr Manufacturing | ||
| Janet Graesser, Senior Relations | ||
| Elvia Cowan, Senior Officer |
Vaxcyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vaxcyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 8.86 B | ||||
| Shares Outstanding | 124.64 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 99.50 % | ||||
| Number Of Shares Shorted | 8.93 M | ||||
| Price To Book | 3.22 X | ||||
| Gross Profit | (23 M) | ||||
| EBITDA | (464.88 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.